Thyroid Cancer: Causes, Types, Diagnosis, and Treatment

What Is Thyroid Cancer?

Thyroid cancer begins in the cells of the thyroid gland, the butterfly-shaped structure sitting just below the larynx. The gland produces thyroxine (T4) and triiodothyronine (T3), hormones that govern metabolism, heart rate, and body temperature. When thyroid cells undergo malignant transformation, they can form nodules that are detectable by ultrasound or palpation. The good news is that most thyroid cancers grow slowly and respond well to established treatments.

The American Cancer Society estimates 43,720 new thyroid cancer diagnoses and 2,120 deaths in the United States in 2023, making thyroid cancer roughly three times more common in women than in men [1]. Incidence has risen steadily since the 1990s, partly because of wider use of neck imaging rather than a true biologic increase in aggressive disease [2].

Types of Thyroid Cancer

Four histologic subtypes account for nearly all thyroid cancers. Understanding which type a patient has determines prognosis, surgical extent, and follow-up intensity.

Papillary thyroid carcinoma (PTC) is by far the most frequent, representing 85 to 90% of cases. It tends to spread to cervical lymph nodes but rarely causes death. The 2015 American Thyroid Association (ATA) guidelines risk-stratify PTC into low, intermediate, and high groups to guide adjuvant therapy decisions [3].

Follicular thyroid carcinoma accounts for roughly 10% of cases. It spreads hematogenously to lung and bone more often than PTC does, and fine-needle aspiration (FNA) alone cannot reliably distinguish follicular carcinoma from follicular adenoma, which means surgical resection is often required for diagnosis [4].

Medullary thyroid carcinoma (MTC) arises from parafollicular C-cells that secrete calcitonin rather than T3/T4. About 25% of MTC cases are hereditary, linked to RET proto-oncogene mutations, making genetic counseling standard practice [5].

Anaplastic thyroid carcinoma is rare (less than 2% of cases) but carries a median survival of roughly four to five months without aggressive multimodal therapy. The FDA approved dabrafenib plus trametinib for BRAF V600E-mutant anaplastic thyroid cancer in 2018, based on data from the ROAR basket trial [6].

How Thyroid Cancer Is Diagnosed

Diagnosis begins with clinical suspicion, often triggered by a palpable nodule or incidental finding on neck imaging ordered for another reason. A systematic workup reduces both under-treatment and unnecessary surgery.

The initial step is a high-resolution neck ultrasound. The American College of Radiology Thyroid Imaging Reporting and Data System (TI-RADS) assigns a score of 1 through 5 based on echogenicity, composition, shape, margin, and echogenic foci, guiding the decision to biopsy [7]. Nodules scoring TI-RADS 4 or 5 and measuring at least 1.5 cm or 1.0 cm, respectively, generally warrant FNA cytology. Bethesda System categories I through VI then classify FNA results from non-diagnostic to malignant, with category VI carrying a greater than 97% risk of malignancy [8].

TSH measurement is obtained at baseline. A suppressed TSH raises concern for a hyperfunctioning (and usually benign) nodule. Serum thyroglobulin is not useful for initial diagnosis but becomes a sensitive marker for disease recurrence after thyroidectomy [9]. Calcitonin screening is debated but recommended by many European guidelines when MTC is suspected clinically [10].

Molecular testing panels such as ThyroSeq v3 and Afirma Gene Sequencing Classifier improve preoperative risk stratification for Bethesda III and IV indeterminate nodules, reducing the proportion of patients who undergo diagnostic surgery for ultimately benign disease [11].

Thyroid Cancer Treatment

Treatment is stratified by histology, stage, and ATA risk category. Surgery is the cornerstone; the extent depends on tumor size, multifocality, and node involvement.

Surgery. Total thyroidectomy is recommended for tumors larger than 4 cm, tumors with extrathyroidal extension, or any high-risk features. Hemithyroidectomy alone is acceptable for unifocal PTC measuring 1 to 4 cm in low-risk patients according to the 2015 ATA guidelines, with equivalent disease-specific survival and lower risk of permanent hypoparathyroidism [3]. A prospective cohort study published in JAMA Surgery (N=18,445) confirmed that hemithyroidectomy in appropriately selected low-risk PTC patients produced 10-year cause-specific survival exceeding 99% [12].

Radioactive iodine (RAI). Post-surgical RAI ablation with iodine-131 is reserved for intermediate- and high-risk patients. The HiLo trial (N=438, published in the New England Journal of Medicine) demonstrated that 1.1 GBq of RAI was non-inferior to 3.7 GBq for remnant ablation success, with a significantly lower rate of short-term side effects [13]. Low-risk patients derive no survival benefit from RAI, and the ATA recommends against routine ablation in that group [3].

TSH suppression. After total thyroidectomy, levothyroxine is dosed to suppress TSH below 0.1 mIU/L in high-risk patients, reducing recurrence risk. For low-risk patients in remission, TSH is maintained in the low-normal range (0.5, 2.0 mIU/L) to minimize long-term cardiovascular and skeletal side effects of over-replacement [3].

Targeted therapy for advanced disease. Kinase inhibitors sorafenib (FDA-approved 2013) and lenvatinib (FDA-approved 2015) are used for radioiodine-refractory differentiated thyroid cancer. The SELECT trial (N=392) showed lenvatinib extended median progression-free survival from 3.6 months (placebo) to 18.3 months (P<0.001) [14].

Hypothyroidism: When the Thyroid Produces Too Little Hormone

Hypothyroidism affects an estimated 4.6% of the U.S. population aged 12 and older, based on data from the NHANES III survey [15]. The thyroid fails to produce enough T3 and T4, causing metabolism to slow. Symptoms include fatigue, cold intolerance, weight gain, constipation, dry skin, and cognitive slowing.

The most common cause in iodine-sufficient countries is Hashimoto's thyroiditis, an autoimmune attack on thyroid tissue. Primary hypothyroidism is confirmed when TSH exceeds the laboratory's upper reference limit (typically 4.5 mIU/L) with a low or low-normal free T4. Treatment is oral levothyroxine, typically starting at 1.6 mcg/kg per day in otherwise healthy adults, with TSH rechecked at 6 to 8 weeks and dose adjusted by 12.5 to 25 mcg increments until euthyroidism is achieved [16].

The American Association of Clinical Endocrinology (AACE) and the American Thyroid Association jointly state: "Levothyroxine is the standard of care for hypothyroidism treatment," with combination T4/T3 therapy reserved for patients who remain symptomatic on levothyroxine monotherapy after other causes have been excluded [17].

Subclinical Hypothyroidism: A Distinct Clinical Decision Point

Subclinical hypothyroidism (SCH) is defined as a TSH between 4.5 and 10 mIU/L with a free T4 within the normal range and no or minimal symptoms. Prevalence is approximately 4 to 8% in the general population, rising to 15 to 18% in women over 60 [18].

Treatment decisions in SCH remain genuinely contested. A randomized controlled trial published in the New England Journal of Medicine (TRUST trial, N=737, mean age 74) found that levothyroxine treatment in older adults with SCH produced no improvement in hypothyroid symptoms or thyroid-related quality of life compared with placebo after 12 months [19]. By contrast, a 2019 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=2,496 across 21 trials) found modest improvements in lipid profiles and left ventricular function in younger patients with TSH above 7 mIU/L who received treatment [20].

Current ATA/AACE guidance recommends treating SCH when TSH exceeds 10 mIU/L regardless of symptoms, when TSH is 4.5, 10 mIU/L in patients younger than 65 with symptoms, or in pregnancy where untreated SCH is associated with adverse obstetric outcomes [17]. Women planning pregnancy should maintain TSH below 2.5 mIU/L, per the 2017 ATA Guidelines for thyroid disease in pregnancy [21].

Hashimoto's Thyroiditis: The Autoimmune Root of Most Hypothyroidism

Hashimoto's thyroiditis (chronic lymphocytic thyroiditis) is the leading cause of hypothyroidism in iodine-replete countries, affecting roughly 1 to 2% of the U.S. population [22]. The immune system generates antibodies, primarily anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin, that gradually destroy thyroid follicular cells.

Clinically, Hashimoto's often presents as a painless goiter with progressive hypothyroid symptoms. Anti-TPO antibodies are elevated in more than 95% of patients and serve as the primary diagnostic marker, though their absolute level does not reliably predict disease severity [23]. Ultrasound typically shows a heterogeneous, hypoechoic gland with a lobulated contour.

Treatment is levothyroxine once overt hypothyroidism develops. Selenium supplementation (200 mcg/day) has been studied as an adjunct to reduce anti-TPO titers; a Cochrane review of 9 randomized trials found selenium significantly lowered anti-TPO antibody levels (mean difference approximately 40%) but noted insufficient evidence to recommend it as standard care given the absence of patient-centered outcome data [24]. Patients with Hashimoto's carry a modestly elevated risk of developing papillary thyroid cancer and thyroid lymphoma, so periodic ultrasound surveillance may be appropriate in those with notable goiters or nodules [25].

Graves' Disease: Autoimmune Hyperthyroidism

Graves' disease causes roughly 80% of all hyperthyroidism cases in the United States [26]. Thyroid-stimulating immunoglobulins (TSIs) mimic TSH and activate the TSH receptor, driving unregulated hormone production. TSH falls below 0.1 mIU/L while free T4 and free T3 are elevated.

Symptoms include palpitations, heat intolerance, unintentional weight loss, tremor, and anxiety. Graves' ophthalmopathy (proptosis, lid retraction, diplopia) affects 25 to 50% of patients and arises from TSI-driven orbital fibroblast activation independent of thyroid status [27].

Three treatment options exist:

1. Antithyroid drugs (ATDs). Methimazole is preferred over propylthiouracil (PTU) except in the first trimester of pregnancy or thyroid storm. A randomized trial published in the Journal of Clinical Endocrinology and Metabolism (N=509) found that 18 months of methimazole produced remission in approximately 50% of patients at 18 months post-discontinuation [28]. Agranulocytosis occurs in roughly 0.3% of patients and requires immediate drug discontinuation.

2. Radioactive iodine (RAI, I-131). RAI ablates overactive thyroid tissue. Most patients become hypothyroid within 6 to 12 months and require lifelong levothyroxine. RAI may worsen active Graves' ophthalmopathy and is contraindicated in pregnancy [29].

3. Thyroidectomy. Total thyroidectomy offers rapid, definitive control and is preferred when the gland is very large, when a concomitant suspicious nodule is present, or when the patient prefers to avoid both radiation and long-term drug therapy [30].

The 2016 ATA Guidelines for Hyperthyroidism state: "All three modalities are acceptable, first-line treatments for Graves' hyperthyroidism; the best choice depends on the clinical situation and patient preference" [30]. Teprotumumab (FDA-approved 2020) is now the standard of care for moderate-to-severe active Graves' ophthalmopathy, reducing proptosis by a mean of 2.82 mm versus 0.54 mm with placebo in the OPTIC trial (N=83, P<0.001) [31].

Risk Factors Connecting Thyroid Conditions

Several risk factors span multiple thyroid disorders, making a unified understanding clinically useful.

Radiation exposure stands out as the best-established environmental risk factor for thyroid cancer. Children exposed to fallout from Chernobyl had a 5- to 10-fold increased incidence of PTC, with risk proportional to absorbed dose [32]. History of head and neck radiation for prior malignancy also elevates lifetime risk and warrants ultrasound surveillance.

Female sex and autoimmunity link Hashimoto's, Graves', and thyroid cancer. Women are three to four times more likely than men to develop autoimmune thyroid disease, and TSH receptor antibodies in Graves' disease have been associated with a small but detectable increase in differentiated thyroid cancer risk in some registry studies [33].

Iodine status modulates disease type. Severe iodine deficiency increases follicular carcinoma incidence; iodine excess may increase the prevalence of autoimmune thyroiditis. The WHO recommends population-level salt iodization to maintain a urinary iodine concentration of 100 to 199 mcg/L in non-pregnant adults [34].

Family history of MTC or multiple endocrine neoplasia type 2 (MEN2) warrants RET germline testing, per National Comprehensive Cancer Network (NCCN) guidelines.

Thyroid Nodule Evaluation: A Clinical Decision Framework

Not every thyroid nodule requires biopsy, and not every biopsy result mandates surgery. A rational evaluation pathway reduces patient anxiety and healthcare costs without sacrificing diagnostic accuracy.

Step 1. Obtain TSH. A suppressed TSH suggests autonomous function; proceed to radionuclide scan. A hyperfunctioning ("hot") nodule almost never harbors malignancy, and biopsy is deferred.

Step 2. Perform neck ultrasound with TI-RADS scoring. Nodules with TI-RADS 1, 2 scores require no FNA regardless of size. TI-RADS 3 nodules warrant FNA only if 2.5 cm or larger.

Step 3. FNA cytology for qualifying nodules. Bethesda I (non-diagnostic) results require repeat FNA under ultrasound guidance. Bethesda V, VI results proceed directly to surgery.

Step 4. Molecular testing for Bethesda III, IV. A benign result on ThyroSeq v3 (negative predictive value ~96%) allows active surveillance instead of diagnostic hemithyroidectomy, sparing a substantial proportion of patients from surgery [11].

Step 5. Post-operative risk stratification. The ATA's three-tier system (low, intermediate, high risk) determines TSH suppression targets, RAI candidacy, and surveillance intervals for thyroglobulin and neck ultrasound.

Clinicians at HealthRX apply this five-step framework to every new thyroid nodule referral before recommending any intervention.

Monitoring After Thyroid Cancer Treatment

Surveillance intensity scales with recurrence risk. For low-risk PTC in remission, the ATA recommends annual TSH measurement, annual thyroglobulin with anti-thyroglobulin antibodies, and neck ultrasound at 6 to 12 months post-surgery, then every 3 to 5 years if findings remain negative [3]. A stimulated thyroglobulin below 1 ng/mL one year after surgery predicts an excellent long-term prognosis with greater than 98% disease-specific survival [35].

For high-risk patients, cross-sectional imaging with CT or PET-CT is added when thyroglobulin rises despite a negative neck ultrasound. Whole-body RAI scan may be performed 6 to 12 months after ablation to confirm completeness of remnant destruction.

Patients on TSH-suppressive levothyroxine doses require bone mineral density monitoring (DEXA) every 1 to 2 years given the long-term skeletal effects of subclinical hyperthyroidism, and atrial fibrillation screening with periodic ECG is advised in those over 60 [36].